AWM
KNSA icon

Avior Wealth Management’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Avior Wealth Management’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-34
Closed -$670 – 3029
2024
Q1 		$670 Buy
+34
New +$664 ﹤0.01% 2489

Other funds holding KNSA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Avior Wealth Management's KNSA Position: Q2 2024 in Review

Avior Wealth Management sold out of Kiniksa Pharmaceuticals (KNSA) in Q2 2024, closing a stake of 34 shares — an estimated $670 sold.

Avior Wealth Management first reported a position in KNSA in Q1 2024 and held it in 1 quarter. The position peaked at $670 in Q1 2024. 133 funds tracked by Wall St. Rank hold KNSA as of Q2 2024.

  • Avior Wealth Management reported no remaining Kiniksa Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Avior Wealth Management sold 34 Kiniksa Pharmaceuticals shares in Q2 2024, an estimated $670.
  • Avior Wealth Management first reported a position in Kiniksa Pharmaceuticals in Q1 2024 and held it in 1 quarter.
  • Avior Wealth Management's Kiniksa Pharmaceuticals position peaked at $670 in Q1 2024.
  • 133 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2024.

Based on Avior Wealth Management's 13F filing for Q2 2024, filed 13 Aug 2024.